Does Incyte Genomics Incorporated (NASDAQ:INCY) Have Gas After Even More Sellers Involved?

January 22, 2018 - By Peter Erickson

 Does Incyte Genomics Incorporated (NASDAQ:INCY) Have Gas After Even More Sellers Involved?

Investors sentiment increased to 1.04 in Q3 2017. Its up 0.02, from 1.02 in 2017Q2. It is positive, as 39 investors sold Incyte Corporation shares while 161 reduced holdings. 59 funds opened positions while 149 raised stakes. 188.97 million shares or 2.28% more from 184.77 million shares in 2017Q2 were reported.
Parametric Limited Liability Co holds 236,789 shares or 0.03% of its portfolio. Sarl owns 202,931 shares. 107,264 were accumulated by Strs Ohio. Envestnet Asset Incorporated invested in 0% or 5,850 shares. 2,295 are owned by Rampart Invest Mngmt Ltd Liability. Moreover, Bb&T Corporation has 0.01% invested in Incyte Corporation (NASDAQ:INCY) for 4,309 shares. Armistice Cap Ltd Company reported 146,000 shares. Raymond James & has 25,438 shares for 0.01% of their portfolio. Connor Clark Lunn Inv Management Ltd reported 0.01% stake. Riverhead Mngmt Ltd Liability Co holds 2,980 shares or 0.02% of its portfolio. Parallax Volatility Advisers L P invested in 25,128 shares or 0% of the stock. The Texas-based Cullen Frost Bankers has invested 0.2% in Incyte Corporation (NASDAQ:INCY). Ubs Oconnor Limited Liability accumulated 144,100 shares. Gam Holding Ag, Switzerland-based fund reported 36,400 shares. Moreover, Artal Group has 0.8% invested in Incyte Corporation (NASDAQ:INCY).

Since August 1, 2017, it had 1 insider purchase, and 9 selling transactions for $325,377 activity. The insider GRYSKA DAVID W sold 6,760 shares worth $668,361. Another trade for 714 shares valued at $88,715 was made by Flannelly Barry P on Wednesday, September 13. $241,914 worth of Incyte Corporation (NASDAQ:INCY) shares were sold by Siegel Eric H.. Stein Steven H had sold 2,111 shares worth $263,875. BAKER BROS. ADVISORS LP bought $13.20 million worth of stock. $415,230 worth of Incyte Corporation (NASDAQ:INCY) shares were sold by Trower Paul.

The stock of Incyte Genomics Incorporated (NASDAQ:INCY) registered an increase of 14.31% in short interest. INCY’s total short interest was 6.97M shares in January as published by FINRA. Its up 14.31% from 6.10 million shares, reported previously. With 1.58M shares average volume, it will take short sellers 4 days to cover their INCY’s short positions. The short interest to Incyte Genomics Incorporated’s float is 4.45%.

The stock increased 1.35% or $1.24 during the last trading session, reaching $93.16. About 1.93M shares traded or 13.72% up from the average. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since January 22, 2017 and is uptrending. It has outperformed by 56.14% the S&P500.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $19.66 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It currently has negative earnings. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 24 analysts covering Incyte (NASDAQ:INCY), 20 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Incyte had 75 analyst reports since August 6, 2015 according to SRatingsIntel. On Sunday, June 4 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Outperform” rating by Oppenheimer given on Friday, February 12. On Thursday, April 7 the stock rating was initiated by BMO Capital Markets with “Outperform”. The firm has “Hold” rating by RBC Capital Markets given on Tuesday, November 21. BMO Capital Markets maintained Incyte Corporation (NASDAQ:INCY) on Thursday, October 12 with “Buy” rating. J.P. Morgan maintained the stock with “Buy” rating in Tuesday, August 1 report. The stock of Incyte Corporation (NASDAQ:INCY) earned “Buy” rating by SunTrust on Tuesday, October 31. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, October 12. Barclays Capital maintained Incyte Corporation (NASDAQ:INCY) on Wednesday, August 10 with “Overweight” rating. The firm earned “Outperform” rating on Thursday, November 12 by Leerink Swann.

More important recent Incyte Corporation (NASDAQ:INCY) news were published by: Seekingalpha.com which released: “Incyte: Low Expectations, Great Growth, Looks Appealing” on January 12, 2018, also Seekingalpha.com published article titled: “Incyte: This ROTY Contender Is On Sale”, Businesswire.com published: “Incyte and Syros Announce Global Target Discovery and Validation Collaboration …” on January 08, 2018. More interesting news about Incyte Corporation (NASDAQ:INCY) was released by: Benzinga.com and their article: “Jim Cramer Advises His Viewers On Incyte And American Outdoor Brands” with publication date: January 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.